Wednesday, October 31, 2012

BioMarin licenses North American rights to rare disease drug, invests $5M in Catalyst Pharmaceutical Partners

Jean-Jacques Bienaime.
BioMarin Pharmaceutical Inc. has licensed North American rights to its rare disease drug Firdapse and is making a $5 million investment in a Florida company that will carry on with a Phase III trial of the drug in the United States.
The investment from Novato-based BioMarin (NASDAQ: BMRN) will help Catalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX) complete an ongoing Phase III clinical trial of Firdapse, which treats patients with the potentially fatal autoimmune disorder Lambert-Eaton Myasthenic Syndrome, or LEMS.
BioMarin will retain its rights to Firdapse elsewhere in the world.

No comments:

Post a Comment